Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dipna PharmachemBOM:543594 -5.00%66 3-Year ROIIC % is 1.67 as of Mar. 2026, which is 61% below its 10-year median of 4.23. GuruFocus rates BOM:543594 with a GF Score™ of 66/100 and a GF Value™ of ₹8.91 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Dipna Pharmachem ranks worse than 53.31% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Dipna Pharmachem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 1.67%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Dipna Pharmachem's 3-Year ROIIC % or its related term are showing as below:
BOM:543594's 3-Year ROIIC % is ranked worse than 53.31% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.66
vs BOM:543594: 1.67
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Dipna Pharmachem 3-Year ROIIC % Related Terms
Dipna Pharmachem 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Dipna Pharmachem (BOM:543594) has a 3-Year ROIIC % of 1.67 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dipna Pharmachem and its competitors. This is 61% below median its historical median of 4.23. Over the past decade, Dipna Pharmachem's 3-Year ROIIC % has ranged from 1.67 to 7.22. According to the industry distribution chart, Dipna Pharmachem ranks #330 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 53.3%.
Is Dipna Pharmachem's 3-Year ROIIC % too high?
Dipna Pharmachem's current 3-Year ROIIC % of 1.67 is 61% below median its 10-year median of 4.23. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 7.22. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.66. Dipna Pharmachem's value of 1.67 is 54.4% below this industry median. Based on the distribution chart, Dipna Pharmachem ranks #330 out of 619 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dipna Pharmachem has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's 3-Year ROIIC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #330 out of 619 companies for 3-Year ROIIC %. This places Dipna Pharmachem in the lower half of its industry. The industry median 3-Year ROIIC % is 3.66. Dipna Pharmachem's value of 1.67 is 54.4% below this benchmark. Historically, Dipna Pharmachem's own 3-Year ROIIC % has ranged from 1.67 to 7.22 over the past decade. While the company's 10-year median is 4.23 vs. the industry median of 3.66, Dipna Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.66, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dipna Pharmachem's current 3-Year ROIIC % of 1.67 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current 3-Year ROIIC % is 1.67, which is 61% below median its own 10-year median of 4.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹8.91, compared to a current price of ₹5.51 — trading 38.2% below its estimated fair value. The current 3-Year ROIIC % is 1.67, which is 61% below median its 10-year median of 4.23 and 54.4% below the Healthcare Providers & Services industry median of 3.66. Dipna Pharmachem's overall GF Score™ is 66/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current 3-Year ROIIC % is 1.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹5.51 is trading 38.2% below its estimated GF Value™ of ₹8.91.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
3-Year ROIIC %: 1.67 (61% below median its 10-year median of 4.23)
GF Value™: ₹8.91 vs. price of ₹5.51 (38.2% below fair value)
Industry Position: 54.4% below the Healthcare Providers & Services median (#330 of 619)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
66GF Score
Get the complete analysis for BOM:543594
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
